Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A
Hubei Hongyuan Pharmaceutical Technology Co., Ltd., together with its subsidiaries, produces and sells pharmaceutical products in China and internationally. The company offers active pharmaceutical ingredients, such as metronidazole, benzoyl metronidazole, dimetrizole, and acyclovir; pharmaceutical intermediates, including imidazole, glyoxylic acid, 2-methyl imidazole, 2-methyl-5-nitroimidazole, … Read more
Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A - Asset Resilience Ratio
Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A (301246) has an Asset Resilience Ratio of 23.49% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2024)
This chart shows how Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.39 Billion | 23.49% |
| Total Liquid Assets | CN¥1.39 Billion | 23.49% |
Asset Resilience Insights
- Good Liquidity Position: Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A maintains a healthy 23.49% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A Industry Peers by Asset Resilience Ratio
Compare Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A (2023–2024)
The table below shows the annual Asset Resilience Ratio data for Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 15.46% | CN¥900.32 Million | CN¥5.82 Billion | -10.48pp |
| 2023-12-31 | 25.94% | CN¥1.47 Billion | CN¥5.65 Billion | -- |